Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 3/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17815743 | 0.89 | IDH1 (0.36) | LRRK2CHRNB4CHRNA3FFAR4APP | |
| SCHEMBL17799055 | 0.87 | LRRK2 (0.36) | LRRK2SCN9ACHRNB4CHRNA3RIPK1 | |
| SCHEMBL17815782 | 0.82 | IDH1 (0.34) | LRRK2CHRNB4CHRNA3FFAR4APP | |
| SCHEMBL17815781 | 0.81 | NPC1 (0.34) | — | |
| SCHEMBL17815699 | 0.79 | MCHR1 (0.43) | CHRNB4CHRNA3 | |
| SCHEMBL17815736 | 0.79 | SCN9A (0.33) | SCN9ACHRNB4CHRNA3FFAR4 | |
| SCHEMBL20820238 | 0.79 | LRRK2 (0.41) | LRRK2SCN9ACHRNB4CHRNA3RIPK1 | |
| SCHEMBL17815779 | 0.78 | ACHE (0.44) | SCN9A | |
| SCHEMBL17815700 | 0.76 | CHRNB4 (0.35) | CHRNB4CHRNA3FFAR4 | |
| SCHEMBL17815721 | 0.76 | CHRNB4 (0.32) | CHRNB4CHRNA3RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | TRPV1, TRPA1, KCNJ2 | LRRK2 1933/4885SCN9A 97/4885CHRNB4 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.